Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
Nelson
Mark
M
Cicuttini
Flavia
F
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002985:Clinical Protocols; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D010003:Osteoarthritis / Q000628:therapy; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib